Synta Pharmaceuticals Corp.


Stock Update (NASDAQ:SNTA): Synta Pharmaceuticals Corp. Reports Third Quarter 2015 Financial Results

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) reported financial results for the third quarter ended September 30, 2015 and provided an update on its business strategy.

Analysts Weigh In on Two Collapsing Healthcare Stocks: Valeant Pharmaceuticals Intl Inc (VRX), Synta Pharmaceuticals Corp. (SNAT)

Analysts are weighing in on the controversial drug giant Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Lexington biotech company Synta Pharmaceuticals Corp. (NASDAQ:SNTA), as shares of both companies fell …

Roth Capital Biotech Insights: Sarepta Therapeutics Inc (SRPT), Synta Pharmaceuticals Corp. (SNTA)

Roth Capital analysts came out with bullish calls on the Cambridge biotech company Sarepta Therapeutics Inc (NASDAQ:SRPT) and Lexington biotech company Synta Pharmaceuticals Corp. (NASDAQ:SNTA), following recent meetings …

Roth Capital Reiterates Buy on Synta Pharmaceuticals Corp. Following Management Meetings

In a research report released today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on shares of Synta Pharmaceuticals Corp. (NASDAQ:SNTA), with a $13 price …

Company Update (NASDAQ:SNTA): Synta Pharmaceuticals Corp. Announces Formation of Expert Oncology Panel

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) announced the formation of anExpert Oncology Panel to provide guidance on research and development strategies for the Company’s portfolio of …

Company Update (NASDAQ:SNTA): Synta Pharmaceuticals Corp. Names Alan C. Rigby, Ph.D. Chief Scientific Officer

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) announced the appointment ofAlan C.

MLV Reiterates Buy On Synta Pharmaceuticals Corp. Following 2Q:15 Results

MLV analyst Arlinda Lee weighed in with a few insights on Synta Pharmaceuticals Corp. (NASDAQ:SNTA), after the company released its second-quarter results and provided update on its pipeline.

Synta Pharmaceuticals Corp. (SNTA) Reports Second Quarter 2015 Financial Results

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) reported financial results for the second quarter ended June 30, 2015 and provided a pipeline update.

Cowen Reiterates Outperform on Synta Pharmaceuticals Corp. Following Ganetespib Program Updates

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) has been reiterated as a Buy at Cowen by research analyst Boris Peaker.

Company Update (NASDAQ:SNTA): Synta Pharmaceuticals Corp. Announces Presentations at the 2015 ASCO Annual Meeting

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) announced that Phase 1 clinical results from three investigator-sponsored trials evaluating ganetespib combination therapy in ALK-positive lung cancer, platinum-resistant ovarian …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts